{"date":"2025-11-25","count":13,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6892-2025-11-25-2306-1ftxbij","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2025-11-25","time":"23:06:40","subject":"本公司Human Umbilical Wharton's Jelly Mesenchymal StemCell Extracellular Vesicles經美國個人護理產品協會(PCPC)審查通過，獲國際INCI新原料認證(INCI name)","clause":"第44款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2025-11-25 23:06，「本公司Human Umbilical Wharton's Jelly Mesenchymal StemCell Extr」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2025-11-25-1847-1ipzoht","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2025-11-25","time":"18:47:09","subject":"公告本公司114年現金增資發行新股認股基準日等相關事宜","clause":"第11款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2025-11-25 18:47，「公告本公司114年現金增資發行新股認股基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3176-2025-11-25-1823-qmpqzy","company_id":"3176","company":"基亞","market":"上櫃","industry":"生技醫療","date":"2025-11-25","time":"18:23:21","subject":"開發中新藥OBP-301進度更新","clause":"第53款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：基亞（3176），2025-11-25 18:23，「開發中新藥OBP-301進度更新」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4726-2025-11-25-1803-1ivhb7h","company_id":"4726","company":"永昕","market":"上櫃","industry":"生技醫療","date":"2025-11-25","time":"18:03:47","subject":"公告本公司董事會同意簽署股東合資協議","clause":"第10款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：永昕（4726），2025-11-25 18:03，「公告本公司董事會同意簽署股東合資協議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7773-2025-11-25-1737-1ejtzv5","company_id":"7773","company":"富禾生醫","market":"興櫃","industry":"生技醫療","date":"2025-11-25","time":"17:37:26","subject":"本公司研發之利用自體培養之EB病毒專一性毒殺T細胞對鼻咽癌病患所進行之免疫療法「EBaT8」，向台灣衛生福利部食品藥物管理署（TFDA）提出第一跨二a期臨床試驗申請。","clause":"第44款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：富禾生醫（7773），2025-11-25 17:37，「本公司研發之利用自體培養之EB病毒專一性毒殺T細胞對鼻咽癌病患所進行之免疫療法「EBaT8」，向台灣衛生福利部食品藥物管」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4153-2025-11-25-1702-68yr6f","company_id":"4153","company":"鈺緯","market":"上櫃","industry":"生技醫療","date":"2025-11-25","time":"17:02:04","subject":"本公司受邀參加福邦證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2025-12-08","cite_as":"公開資訊觀測站重大訊息：鈺緯（4153），2025-11-25 17:02，「本公司受邀參加福邦證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4743-2025-11-25-1644-10faqd0","company_id":"4743","company":"合一","market":"上櫃","industry":"生技醫療","date":"2025-11-25","time":"16:44:59","subject":"公告本公司FB825應用於治療IgE介導的過敏性疾病之專利取得韓國專利證書","clause":"第53款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：合一（4743），2025-11-25 16:44，「公告本公司FB825應用於治療IgE介導的過敏性疾病之專利取得韓國專利證書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4147-2025-11-25-1620-1a5udqu","company_id":"4147","company":"中裕","market":"上櫃","industry":"生技醫療","date":"2025-11-25","time":"16:20:18","subject":"中裕新藥世界首創長效型雙抗體愛滋病療法TMB-365/TMB-380榮獲第二十二屆國家新創獎","clause":"第53款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：中裕（4147），2025-11-25 16:20，「中裕新藥世界首創長效型雙抗體愛滋病療法TMB-365/TMB-380榮獲第二十二屆國家新創獎」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4139-2025-11-25-1609-1roellr","company_id":"4139","company":"馬光-KY","market":"上櫃","industry":"生技醫療","date":"2025-11-25","time":"16:09:40","subject":"公告本公司董事辭任","clause":"第6款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：馬光-KY（4139），2025-11-25 16:09，「公告本公司董事辭任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6637-2025-11-25-1544-fn5aok","company_id":"6637","company":"醫影","market":"上櫃","industry":"生技醫療","date":"2025-11-25","time":"15:44:05","subject":"本公司受邀參加富邦證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-11-26","cite_as":"公開資訊觀測站重大訊息：醫影（6637），2025-11-25 15:44，「本公司受邀參加富邦證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2025-11-25-1508-1ppi0i3","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2025-11-25","time":"15:08:48","subject":"本公司收回已發行之限制員工權利新股辦理註銷減資變更登記完成","clause":"第36款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2025-11-25 15:08，「本公司收回已發行之限制員工權利新股辦理註銷減資變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2025-11-25-1507-1ffxuo3","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2025-11-25","time":"15:07:53","subject":"公告本公司辦理庫藏股註銷減資變更登記完成","clause":"第36款","fact_date":"2025-11-25","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2025-11-25 15:07，「公告本公司辦理庫藏股註銷減資變更登記完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4121-2025-11-25-1433-16sohr8","company_id":"4121","company":"優盛","market":"上櫃","industry":"生技醫療","date":"2025-11-25","time":"14:33:46","subject":"本公司受邀參加元大證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2025-11-26","cite_as":"公開資訊觀測站重大訊息：優盛（4121），2025-11-25 14:33，「本公司受邀參加元大證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}